Drugs that contain Baricitinib
1. Olumiant patents expiration
OLUMIANT's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8158616 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Jun, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420629 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Mar, 2029
(4 years from now) | |
| US9737469 | ELI LILLY AND CO | Methods for treating hair loss disorders |
Nov, 2031
(7 years from now) | |
| US11806555 | ELI LILLY AND CO | Methods for treating hair loss disorders |
Nov, 2031
(7 years from now) | |
| US11045474 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections |
Nov, 2032
(8 years from now) | |
| US9089574 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-890) | Jun 13, 2025 |
| New Indication(I-891) | May 10, 2025 |
| New Chemical Entity Exclusivity(NCE) | May 31, 2023 |
NCE-1 date: 31 May, 2022
Market Authorisation Date: 08 October, 2019
Treatment: Treatment of rheumatoid arthritis; Treatment of adult patients with severe alopecia areata; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-i...
Dosage: TABLET;ORAL
How can I launch a generic of OLUMIANT before it's drug patent expiration?
More Information on Dosage
OLUMIANT family patents
